Options for Patients With Melanoma Who Have Exhausted Standard Therapies
Omid A. Hamid, MD, chief of Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses options for patients with melanoma who have exhausted standard therapies.
Omid A. Hamid, MD, chief of Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses options for patients with melanoma who have exhausted standard therapies.
Ongoing clinical trials are exploring whether adding other agents to standard therapies will be able to turn some of these patients into responders again, such as adding an IDO inhibitor to standard PD-1 therapy. Additional questions are whether adoptive T cell therapy can be made available to more patients.
Management of Immune-Related Toxicities in Melanoma Has Improved Over Time
April 24th 2024During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants how their experience with immunotherapy toxicities has changed over time in the first article of a 2-part series.
Read More
